Literature DB >> 28602517

Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: A meta-analysis?

Guihua Tang1, Wen Yin2, Wenen Liu3.   

Abstract

Fecal microbiota transplantation (FMT) is a remarkably efficacious therapy for recurrent or refractory Clostridium difficile infection (CDI), but not standardized. This work is to determine whether frozen FMT is as effective as fresh FMT. Meta-analysis showed that frozen FMT was as effective as fresh FMT, both pooled first effective rate (65.0% (95% CI 57.0-73.0%) vs. 65.0% (95% CI 57.0-73.0%), P=0.962) and pooled second effective rate (95.0% (95% CI 91.0-99.0%) vs. 95.0% (95% CI 92.0-99.0%), P=0.880). In conclusion, among patients with recurrent or refractory CDI, frozen FMT is as effective as fresh FMT. Considering potential advantages of performing frozen FMT, it is a reasonable option to select frozen FMT.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Fresh fecal microbiota transplantation; Frozen fecal microbiota transplantation

Mesh:

Year:  2017        PMID: 28602517     DOI: 10.1016/j.diagmicrobio.2017.05.007

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  23 in total

Review 1.  Technical Aspects of Fecal Microbial Transplantation (FMT).

Authors:  N Bhutiani; J E Schucht; K R Miller; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

2.  Comparative methods for fecal sample storage to preserve gut microbial structure and function in an in vitro model of the human colon.

Authors:  Charlotte Deschamps; Elora Fournier; Ophélie Uriot; Frédérique Lajoie; Cécile Verdier; Sophie Comtet-Marre; Muriel Thomas; Nathalie Kapel; Claire Cherbuy; Monique Alric; Mathieu Almeida; Lucie Etienne-Mesmin; Stéphanie Blanquet-Diot
Journal:  Appl Microbiol Biotechnol       Date:  2020-10-21       Impact factor: 4.813

3.  Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis.

Authors:  Guihua Tang; Wen Yin; Youde Cao; Liming Tan; Shuyu Wu; Yudong Cao; Xianyong Fu; Jing Yan; Xingjun Jiang
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452

4.  Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement.

Authors:  Susy S Hota; Salman Surangiwala; Aimee S Paterson; Bryan Coburn; Susan M Poutanen
Journal:  CMAJ Open       Date:  2018-04-18

Review 5.  From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation.

Authors:  Carole Nicco; Armelle Paule; Peter Konturek; Marvin Edeas
Journal:  Diseases       Date:  2020-04-15

Review 6.  Fecal microbiota transplantation in alcohol related liver diseases.

Authors:  Saggere Muralikrishna Shasthry
Journal:  Clin Mol Hepatol       Date:  2020-06-23

Review 7.  Fecal transplantation: digestive and extradigestive clinical applications.

Authors:  Mihaela Filip; Valentina Tzaneva; Dan L Dumitrascu
Journal:  Clujul Med       Date:  2018-07-31

Review 8.  Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review.

Authors:  Simon D Goldenberg; Rahul Batra; Ian Beales; Jonathan Leith Digby-Bell; Peter Miles Irving; Lee Kellingray; Arjan Narbad; Ngozi Franslem-Elumogo
Journal:  Infect Dis Ther       Date:  2018-02-15

Review 9.  Microbiota transplantation: concept, methodology and strategy for its modernization.

Authors:  Faming Zhang; Bota Cui; Xingxiang He; Yuqiang Nie; Kaichun Wu; Daiming Fan
Journal:  Protein Cell       Date:  2018-04-24       Impact factor: 14.870

10.  Fecal microbiota transplantation for recurrent Clostridium difficile infection: Experience, protocol, and results.

Authors:  E Reigadas; M Olmedo; M Valerio; S Vázquez-Cuesta; L Alcalá; M Marín; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2018-09-14       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.